Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report

Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evid...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2019-12, Vol.18 (6), p.6469-6474
Main Authors: Takeuchi, Nobumichi, Koike, Kumiko, Yoshida, Sonomi, Fujiwara, Masayuki
Format: Article
Language:English
Subjects:
Cancer therapies
Case reports
Chemotherapy
Colorectal cancer
Dyspnea
Hematology
Hospitals
Inhibitor drugs
Lung cancer
Medical prognosis
Metastasis
NMR
Nuclear magnetic resonance
Oncology
Patients
Permeability
Respiratory failure
Studies
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evidence of a response to these drugs is scarce. Herein, the present study reports the case of a patient with rectal cancer refractory to multiple surgical interventions and standard chemotherapy. Treatment with regorafenib resulted in immediate improvement of respiratory failure caused by pulmonary lymphangitic carcinomatosis. This improvement persisted for over 3 months and was confirmed by radiology. Our findings suggest that regorafenib can reduce peritumoral edema via its interaction with the vascular endothelial growth factor receptor. Thus, regorafenib functions as a multityrosine kinase inhibitor to alleviate symptoms of lymphangitic carcinomatosis despite the low potency of the drug.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2019.11043